Uterine fibroids: hiding in plain sight

EA Stewart, RA Nowak - Physiology, 2022 - journals.physiology.org
Uterine fibroids (leiomyomas) are present in> 75% of women and can cause serious
morbidity. They are by far the leading cause of hysterectomy. Fibroids are a complex mixture …

Linzagolix: a new GnRH-antagonist under investigation for the treatment of endometriosis and uterine myomas

S Dababou, S Garzon, AS Laganà… - Expert opinion on …, 2021 - Taylor & Francis
Introduction Uterine myomas and endometriosis are benign hormone-dependent diseases
affecting women of reproductive age. Substantial efforts have been made to develop …

Evidence for gastrointestinal infection of SARS-CoV-2

F Xiao, M Tang, X Zheng, Y Liu, X Li, H Shan - Gastroenterology, 2020 - gastrojournal.org
Methods From February 1 to 14, 2020, clinical specimens, including serum,
nasopharyngeal, and oropharyngeal swabs; urine; stool; and tissues from 73 hospitalized …

Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind, studies …

LC Giudice, S As-Sanie, JCA Ferreira, CM Becker… - The Lancet, 2022 - thelancet.com
Background Endometriosis is a common cause of pelvic pain in women, for which current
treatment options are suboptimal. Relugolix, an oral gonadotropin-releasing hormone …

Treatment of uterine fibroid symptoms with relugolix combination therapy

A Al-Hendy, AS Lukes, AN Poindexter III… - … England Journal of …, 2021 - Mass Medical Soc
Background Uterine fibroids are a common cause of heavy menstrual bleeding and pain.
Treatment with the combination of relugolix (an oral gonadotropin-releasing hormone …

Linzagolix with and without hormonal add-back therapy for the treatment of symptomatic uterine fibroids: two randomised, placebo-controlled, phase 3 trials

J Donnez, HS Taylor, EA Stewart, L Bradley, E Marsh… - The Lancet, 2022 - thelancet.com
Background Uterine fibroids are common non-cancerous neoplasm that cause heavy
menstrual bleeding and other signs. Linzagolix is an oral gonadotropin-releasing hormone …

The role of endocrine-disrupting chemicals in uterine fibroid pathogenesis

MV Bariani, R Rangaswamy, H Siblini… - Current Opinion in …, 2020 - journals.lww.com
While research on EDCs and fibroids is still evolving, recent evidence suggests EDC
exposures may contribute to fibroid risk and progression. Further research is needed to …

Uterine fibroids: assessing unmet needs from bench to bedside

IO Aninye, MH Laitner… - Journal of Women's …, 2021 - liebertpub.com
Uterine fibroids (leiomyomas) are noncancerous growths that can have deleterious effects
on the health and quality of life for millions of women. Attempts to better understand the …

[HTML][HTML] Uterine artery embolisation versus myomectomy for premenopausal women with uterine fibroids wishing to avoid hysterectomy: the FEMME RCT.

J Daniels, LJ Middleton, V Cheed… - Health Technology …, 2022 - ncbi.nlm.nih.gov
BACKGROUND Uterine fibroids are the most common tumour in women of reproductive age
and are associated with heavy menstrual bleeding, abdominal discomfort, subfertility and …

Conservative management of uterine fibroid-related heavy menstrual bleeding and infertility: time for a deeper mechanistic understanding and an individualized …

MM Dolmans, L Cacciottola, J Donnez - Journal of clinical medicine, 2021 - mdpi.com
(1) Background: Uterine fibroids are the most common form of benign uterine tumors,
causing heavy menstrual bleeding (HMB), pelvic pain, infertility and pressure symptoms …